Clinical trial NCT01924026: Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
Official title: Neuropsychological and Quality of Life Outcomes in Untreated Adults With Mild Hyperphenylalaninemia (MHP)/Phenylketonuria (PKU) With Phenylalanine Levels Between 360 and 600 µmol/L Caused by Phenylalanine Hydroxylase (PAH) Deficiency.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Phenylketonuria
Mild Hyperphenylalaninemia
Keywords: Phenylketonuria
Mild Hyperphenylalaninemia
PKU
MHP
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
Collaborators: name: BioMarin Pharmaceutical
First posted: 2013-08-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Those with mild form of PKU known as mild hyperphenylalaninemia (MHP) and their unaffected siblings who fulfill the inclusion and exclusion criteria.

Brief summary: Phenylketonuria (PKU) is a genetic disorder known to cause severe reduction in intelligence and deficits in cognitive function; it is associated with an elevated level of Phenylalanine (Phe) in blood.

Newborn screening and early treatment with restricted protein diet supplemented by a formula of amino-acids will preserve intelligence. In those with the severe form treated from birth, some deficits that affect higher functions of the brain are seen.

Given this, there is disagreement about how milder forms of this disease should be managed and what level of Phe is safe to be left untreated.

We seek to assess whether higher Phe levels, between 360 and 600µmol/L, are safe with respect to preservation of intelligence and higher cognitive functions.

Detailed description: The following personal/medical information will be collected and reviewed:

* Evaluation of current and past medical history, including psychological treatment such as medication and counseling/therapy.
* Mutational analysis for each MHP subject
* Detailed history of educational, employment, relationship, and socioeconomic status/achievements as a measure of successful transition to adulthood
* Diet history, including past treatment with medical food or Sapropterin (Kuvan) for pre-conceptual and pregnancy Phe management
* All available untreated Phe levels, including newborn screening results (where possible) will be collated to calculate lifetime mean Phe level. Age at collections will be recorded separately for each MHP subjects to ensure inclusion of Phe levels beyond infancy

The following clinical investigations will be administered:

* Measurement of Phe and Tyrosine after an overnight fast, via blood spot using tandem mass spectrometry analysis. Blood spot collection will be done at the same time of day for all subjects.
* Physical exam, height and weight measurements
* Food Frequency Questionnaire assessment to estimate typical daily intake of natural protein.
* Self-Report Questionnaires:

  * Behavior Rating Inventory of Executive Function (BRIEF)-A
  * Beck Anxiety Inventory
  * Beck Depression Inventory
  * Quality of Life questionnaire
* Neuropsychological Tests assessed by a trained psychologist

An informant BRIEF-A report will be completed for each subject. To ensure consistency in rating, the same informant will be used where possible for the MHP subject and their sibling control (i.e. parents). These questionnaires will be mailed to the informants and returned to the study site via FedEx.

Eligibility criteria: Inclusion Criteria:

* Male or Female, ≥ 18 years
* Confirmed to have MHP with at least two Phe levels during lifetime of above 360µmol/L and below 600µmol/L, including newborn screening levels (available since 1968 by either bacterial inhibition, enzymatic or tandem mass spectrometry methodology) and via mutation analysis. Those with occasional levels above 600µmol/L will not be excluded provided the majority of available levels fall within the 360-600µmol/L range.
* On an unrestricted diet and not taking medical food. Women who were on dietary or Kuvan® treatment for past pre-conception or pregnancy management will not be excluded
* Willing and able to give consent and comply with study procedures.

Exclusion Criteria:

* Subjects on dietary or Kuvan® treatment within the last 12 weeks will be excluded.
* Co-morbidities that may interfere with study participation and/or put the subject at a higher risk of adverse effects.

Subjects who do not have an unaffected sibling may still participate.

Primary outcomes:
measure: Executive function
timeFrame: Day 1
Secondary outcomes:
measure: Quality of Life
timeFrame: Day 1
measure: Presence of anxiety and depression
timeFrame: Day 1
Other outcomes:
measure: IQ
timeFrame: Day 1
Locations:
city: Toronto
country: Canada
facility: The Hospital for Sick Children
state: Ontario
Study officials:
affiliation: The Hospital for Sick Children
name: Annette Feigenbaum, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Stollery Children's Hospital
name: Komudi Siriwardena, MD
role: PRINCIPAL_INVESTIGATOR
References: